Phase 3 topline data expected 2Q25 for epetraborole in patients with treatment-refractory MAC lung disease (TR MAC) Phase 1 first in human study of AN2-502998, under development for Chagas disease, to ...
AN2 Therapeutics is rethinking its business in response to lackluster midphase data, vowing to lay off half its employees and stop a phase 3 study as part of a pivot to early-stage projects. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results